UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549

 

SCHEDULE 14A

(RULE 14a-101)

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant Toto Section 14(a) of the
Securities

Exchange Act of 1934

(Amendment No.  )

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Filed by the Registrant [X]
Filed by a party other than the Registrant [  ]

 

Check the appropriate box:Appropriate Box:

 

[  ]Preliminary Proxy Statement
[  ] 
Confidential, for useUse of the Commission Only (as permittedPermitted by Rule 14a-6(e)(2))
[X] 
þDefinitive Proxy Statement
[  ] 
Definitive Additional Materials
[  ] 
Soliciting Material Pursuant to § 240.14a-12§240.14a-12

 

SHINECO, INC.

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement if Other Thanother than the Registrant)

 

Payment of Filing Feefiling fee (Check the appropriate box):

 

[X]No fee required.
  
[  ]Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.0-11

(1)

Title of each class of securities to which transaction applies:

  
(2)

Aggregate number of securities to which transaction applies:

  
(3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

  
(4)

Proposed maximum aggregate value of transaction:

  
(5)

Total fee paid:

  (5)Total fee paid:

[  ]Fee paid previously with preliminary materials:

materials.
  
[  ]Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  
(1)

Amount Previously Paid:

  (1)Amount Previously Paid:
(2)

Form, Schedule or Registration Statement No.:

  
(3)

Filing Party:

  (3)Filing Party:
(4)

Date Filed:

 

 

 

 

SHINECO, INC.
Room 1001, Building T5,
DaZu Square, Daxing District,
Beijing, People’s Republic of China

 

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

To Be Held at 9:00 p.m. on June 19, 2018 Eastern Standard TimeSHINECO, INC.

To the Stockholders of Shineco, Inc.:

This proxy statement is furnished in connection with the solicitation of proxies by the Board of Directors (the“Board”) of Shineco, Inc. (the“Company” ) for use at the 2018 annual meeting of stockholders of the Company (the“Meeting” ) and at all adjournments and postponements thereof. The Meeting will be held Room 1001, Building T5, DaZu Square

Daxing District, Beijing 100176

People’s Republic of China on Tuesday, June 19, 2018, at 9:00 p.m. EST, to consider and vote upon the following proposals:

Notice of Annual Meeting of Stockholders

 

Date:June 15, 2021
Time:9:00 p.m. EST
Location:Room 3106, Building B, Jianwai SOHO,
Chaoyang District, Beijing 100022
People’s Republic of China
Record Date:April 30, 2021

Proposals:

1.To re-elect Yuying Zhang, Sai (Sam) Wang, Jiping Chen, Ying (Teresa) Zhang, Yajun Shi, Leiger Yongman Yang, and Hua Yang (the“Director Nominees”)Re-elect seven directors to serve on the Company’s Board of Directors (the Board“Board”) until the next annual shareholders meeting andof Shineco, Inc. (the “Company”) to serve until their successors are duly re-electedelected and qualified;qualified at the 2022 annual meeting of stockholders or until their earlier resignation or removal; and

2.To re-appoint Wei WeiRatify the appointment of Centurion ZD CPA & Co., LLP (“WeiCZD”) as the Company’s independent registered public accounting firm of the Company for the fiscal year ending June 30, 2018.2021.

 

THE BOARD UNANIMOUSLY RECOMMENDS ATHAT YOU VOTE “FOR” ALLEACH OF THE DIRECTOR NOMINEES LISTED ABOVEINCLUDED IN PROPOSAL NO. 1 AND “FOR” PROPOSAL No.NO. 2.

 

Holders of record of the Company’s Common Stockcommon stock at the close of business on May 2, 2018April 30, 2021 (the“Record “Record Date”) will be entitled to notice of, and to vote at, this Meetingthe 2021 annual meeting of stockholders of the Company (the “Meeting”) and any adjournment or postponement thereof. Each share of Common Stockcommon stock entitles the holder thereof to one vote.

 

Your vote is important, regardless of the number of shares you own. Even if you plan to attend thisthe Meeting in person, it is strongly recommended that you complete the enclosed proxy card before the meeting date, to ensure that your shares will be represented at thisthe Meeting if you are unable to attend.

 

A complete list of stockholders of record entitled to vote at thisthe Meeting will be available for ten10 days before thisthe Meeting at the principal executive office of the Company for inspection by stockholders during ordinary business hours for any purpose germane to thisthe Meeting.

 

This notice and the enclosed proxy statement are first being mailed to stockholders on or about June 1, 2018.May 12, 2021.

 

You are urged to review carefully the information contained in the enclosed proxy statement prior to deciding how to vote your shares.

 

 By Order of the Board,
  
 
Date:May 10, 2021By:

/s/ Yuying ZhangOu Yang

 Yuying ZhangName:Ou Yang
 Title:

Chief Executive Officer

May 30, 2018

(Principal Executive Officer)

 

IF YOU RETURN YOUR PROXY CARD WITHOUT AN INDICATION OF HOW YOU WISH TO VOTE, YOUR SHARES WILL BE VOTED “FOR” ALL OF THE NOMINEESPROPOSALS LISTED ABOVE AND “FOR” EACH OF THE OTHER PROPOSALS.ABOVE.

 

Important Notice Regarding the Availability of Proxy Materials

for the 2021 Annual Stockholder Meeting of Stockholders to Be Heldbe held at 9:00 p.m. EST on June 19, 2018 Eastern Standard Time15, 2021

 

The Notice of the Annual Meeting of Stockholders, this proxy statement, and our Annual Report on Form 10-K for the period ended June 30, 2020 (the “Annual Report”) are available at comwww.proxyandprinting.com.http://tianyiluobuma.com.

 

 

 

TABLE OF CONTENTSTable of Contents

 

 Page
QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALSNotice of Annual Meeting of Stockholders
Questions and Answers about these Proxy Materials1
THE ANNUAL MEETING3
General3
Date, Time Information about the Meeting and Place of the Meeting3
Purpose of the MeetingVoting4
Record Date and Voting Power4
Quorum and Required Vote4
Revocability of Proxies4
Proxy Solicitation Costs4
No Right of Appraisal4
Who Can Answer Your Questions About Voting Your Shares5
Principal Officers5
PROPOSAL NO.Proposal No. 1 — RE-ELECTION OF DIRECTORSRe-Election of Directors5
Board Qualifications and Director NomineesNominee Information56
Information Regarding the Company's DirectorsCorporate Governance Practices and Nominees5
Vote RequiredPolicies7
Recommendation of the Board and Committee Independence7
Corporate GovernanceBoard Committees and Meetings7
Director CompensationBoard Role in Risk Oversight9
ExecutiveCode of Conduct and Ethics9
Family Relationships9
Legal Proceedings Involving Officers and Directors10
Executive CompensationStockholder Communications with the Board10
Section 16 ComplianceDirector Compensation10
Executive Officers11
Executive Compensation11
Section 16 (a) Compliance12
Security Ownership of Certain Beneficial Owners and Management1112
Certain Relationships and Related Party Transactions12
PROPOSAL NO. 2 — REAPPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM13
Principal Accountant Fees and ServicesProposal No. 2 — Ratification of Appointment of Independent Registered Public Accounting Firm1314
Change of Independent Registered Public Accounting Firm15
Fees Paid to the Independent Registered Public Accounting Firm15
Policies and Procedures Relating to Approval of Services by our Independent Registered Public Accountants1316
Vote Required13
Recommendation of the Board14
Audit Committee Report14
16
OTHER MATTERSOther Matters14
17
OTHER INFORMATIONOther Important Information1417
Deadline for Submission of Stockholder Proposals for 2018 ANNUAL MEETING OF STOCKHOLDERS2022 Annual Meeting of Stockholders1417
Proxy Solicitation1517
Annual Report1517
Delivery of Proxy Materials to Households1517
Where You Can Find Additional Information1518

 

i

i

 

 

SHINECO, INC.
PROXY STATEMENT
Questions and Answers about these Proxy Materials

 

2018 ANNUAL MEETING OF STOCKHOLDERS

to be held on Tuesday, June 19, 2018, at 9:00 p.m., Eastern Standard Time
Room 1001, Building T5,
DaZu Square, Daxing District,
Beijing, People’s Republic of China

QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS

Why am I receiving this proxy statement?

In this proxy statement, we refer to Shineco, Inc. as the “Company,” “we,” “us,” or “our.”

 

This proxy statement describes the proposals on which our Board would like you, as a stockholder, to vote at the Meeting, which will take place on Tuesday, June 19, 2018,15, 2021 at 9:00 p.m., EST, at Room 1001,3106, Building T5, DaZu Square, DaxingB, Jianwai SOHO, Chaoyang District, Beijing, 100022, People’s Republic of China.

 

Stockholders are being asked to consider and vote upon proposals to (i) re-elect the Director Nomineesseven directors to the Board to serve one-year terms,until their successors are duly elected and qualified at the 2022 annual meeting of stockholders or until their earlier resignation or removal, and (ii) re-appoint Weiratify the appointment of CZD as our independent registered public accounting firm for the fiscal year ending June 30, 2018, and (iii) transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.2021.

 

This proxy statement also gives you information on the proposals so that you can make an informed decision. You should read it carefully.Your vote is important.You are encouraged to submit your proxy card as soon as possible after carefully reviewing this proxy statement.

 

In this proxy statement, we refer to Shineco, Inc. as the “Company”, “the Company,” “we,” “us,” or “our.”

Who can vote at thisthe Meeting?

 

Stockholders who owned shares of our Common Stockcommon stock on May 2, 2018 (the “the Record Date”) may attend and vote at thisthe Meeting. There were 21,234,0724,009,288 shares of Common Stockcommon stock outstanding on the Record Date. All shares of Common Stockcommon stock shall have one vote per share. Information about the stockholdings of our directors, executive officers, and significant stockholders is contained in the section of this proxy statement entitled “Security Ownership of Certain Beneficial Owners and Management” beginning on page 1112 of this proxy statement.

 

What is the proxy card?

 

The card enables you to appoint Yuying ZhangYanzeng An as your representative at thisthe Meeting. By completing and returning the proxy card, you are authorizing this person to vote your shares at thisthe Meeting in accordance with your instructions on the proxy card. This way, your shares will be voted whether or not you attend thisthe Meeting. Even if you plan to attend thisthe Meeting, it is strongly recommended to complete and return your proxy card before thisthe Meeting date just in case your plans change. If a proposal comes up for vote at thisthe Meeting that is not on the proxy card, the proxy will vote your shares, under your proxy, according to his best judgment.

 

How does the Board recommend that I vote?

 

Our Board unanimously recommends that stockholders vote “FOR” each of the Director Nomineesdirector nominees listed in proposal No. 1 and “FOR” proposal No. 2.

 

What is the difference between holding shares as a stockholder of record and as a beneficial owner?

 

Certain of our stockholders hold their shares in an account at a brokerage firm, bank, or other nominee holder, rather than holding share certificates in their own name. As summarized below, there are some distinctions between shares held of record and those owned beneficially.

 

1

Stockholder of Record/Registered Stockholders

If, on the Record Date, your shares were registered directly in your name with our transfer agent, Island Stock Transfer, LLC,Transhare Corporation, you are a “stockholder of record” who may vote at the Meeting, and we are sending these proxy materials directly to you. As the stockholder of record, you have the right to direct the voting of your shares by returning the enclosed proxy card to us or to vote in person at the Meeting. Whether or not you plan to attend the Meeting, please complete, date, and sign the enclosed proxy card to ensure that your vote is counted.

 

Beneficial Owner

If, on the Record Date, your shares were held in an account at a brokerage firm or at a bank or other nominee holder, you are considered the beneficial owner of shares held “in street name,” and these proxy materials are being forwarded to you by your broker or nominee who is considered the stockholder of record for purposes of voting at the Meeting. As the beneficial owner, you have the right to direct your broker on how to vote your shares and to attend the Meeting. However, since you are not the stockholder of record, you may not vote these shares in person at the Meeting unless you receive a valid proxy from your brokerage firm, bank, or other nominee holder. To obtain a valid proxy, you must make a special request of your brokerage firm, bank, or other nominee holder. If you do not make this request, you can still vote by using the voting instruction card enclosed with this proxy statement; however, you will not be able to vote in person at the Meeting.

How do I vote?

 

If you were a stockholder of record of the Company’s Common Stockcommon stock on the Record Date, you may vote in person at the Meeting or by submitting a proxy. Each share of Common Stockcommon stock that you own in your name entitles you to one vote, in each case, on the applicable proposals.

 

(1)You may submit your proxy by mail. You may submit your proxy by mail by completing, signing and dating your proxy card and returning it in the enclosed, postage-paid and addressed envelope. If we receive your proxy card prior to this Meeting and if you mark your voting instructions on the proxy card, your shares will be voted:

(1)You may submit your proxy by mail. You may submit your proxy by mail by completing, signing, and dating your proxy card and returning it in the enclosed, postage-paid, and addressed envelope. If we receive your proxy card prior to the Meeting and if you mark your voting instructions on the proxy card, your shares will be voted:

 

 as you instruct, and
 according to the best judgment of the proxies if a proposal comes up for a vote at thisthe Meeting that is not on the proxy card.

 

We encourage you to examine your proxy card closely to make sure you are voting all of your shares in the Company.

 

If you return a signed card, but do not provide voting instructions, your shares will be voted:

 

 FOR each nominee for director;
 
FOR the selection of WeiCZD as our independent registered public accounting firm for the fiscal year ending June 30, 2018;2021; and
   
 According to the best judgment of Yuying ZhangYanzeng An if a proposal comes up for a vote at the Meeting that is not on the proxy card.

 

(2)You may vote in person at the Meeting
(2)You may vote in person at the Meeting.. We will pass out written ballots to any stockholder of record who wants to vote at the Meeting.

 

If I plan on attending the Meeting, should I return my proxy card?

 

Yes. Whether or not you plan to attend the Meeting, after carefully reading and considering the information contained in this proxy statement, please complete and sign your proxy card. Thencard, and then return the proxy card in the pre-addressed, postage-paid envelope provided herewith as soon as possible, so your shares may be represented at the Meeting.

 

May I change my mind after I return my proxy?

 

Yes. You may revoke your proxy and change your vote at any time before the polls close at thisthe Meeting. You may do this by:

 

 sending a written notice to the Secretary of the Company at the Company’s executive offices stating that you would like to revoke your proxy of a particular date;
 
signing another proxy card with a later date and returning it to the Secretary before the polls close at thisthe Meeting; or
 attending thisthe Meeting and voting in person.

 

2

What does it mean if I receive more than one proxy card?

 

You may have multiple accounts at the transfer agent and/or with brokerage firms. Please sign and return all proxy cards to ensure that all of your shares are voted.

 

What happens if I do not indicate how to vote my proxy?

 

Signed and dated proxies received by the Company without an indication of how the stockholder desires to vote on a proposal will be voted in favor of each director and proposal presented to the stockholders.

 

Will my shares be voted if I do not sign and return my proxy card?

 

If you do not sign and return your proxy card, your shares will not be voted unless you vote in person at thisthe Meeting.

 

What vote is required to re-elect the Director Nomineesdirector nominees as directors of the Company?

 

The electionre-election of each nominee for director requires the affirmative vote of a plurality of the shares of Common Stockcommon stock represented in person or by proxy and entitled to vote in the electionre-election of directors at the Meeting.

 

How many votes are required to re-appoint Weiappoint CZD as the Company’s independent registered public accounting firm for fiscal year ending June 30, 2018?2021?

 

The proposal to re-appoint Weiappoint CZD to serve as our independent registered public accounting firm for 2018the fiscal year ending June 30, 2021 requires the affirmative vote of a majority of the votes cast at the Meeting by the holders of shares of Common Stockcommon stock entitled to vote.

 

Is my vote kept confidential?

 

Proxies, ballots, and voting tabulations identifying stockholders are kept confidential and will not be disclosed, except as may be necessary to meet legal requirements.

 

Where do I find the voting results of thisthe Meeting?

 

We will announce voting results at thisthe Meeting and also file a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (the SEC“SEC”) reporting the voting results.

 

Who can help answer my questions?

 

You can contact Yuying Zhang at (+86) 10-8722736610-58693193 or by sending a letter to the offices of the Company at Room 1001, Building T5, DaZu Square, Daxing District, Beijing 100176, People’s Republic of China with any questions about proposals described in this proxy statement or how to execute your vote.

3

THE ANNUAL MEETING

General Information about the Meeting and Voting

 

General

We are furnishing this proxy statement to you, as a stockholder of Shineco, Inc., as part of the solicitation of proxies by our Board for use at the Meeting to be held on June 19, 2018,15, 2021, and any adjournment or postponement thereof. This proxy statement is first being furnished to stockholders on or about June 1, 2018.May 12, 2021. This proxy statement provides you with information you need to know to be able to vote or instruct your proxy how to vote at the Meeting.

Date, Time and Place of the Meeting

The Meeting will be held on June 19, 2018, at 9:00 p.m., EST, at Room 1001, Building T5, DaZu Square, Daxing District, Beijing, People’s Republic of China, or such other date, time and place to which the Meeting may be adjourned or postponed.

Date, Time, and Place of the MeetingThe Meeting will be held on June 15, 2021, at 9:00 p.m., EST, at Room 3106, Building B, Jianwai SOHO, Chaoyang District, Beijing, 100022, People’s Republic of China, or such other date, time, and place to which the Meeting may be adjourned or postponed.
 3 

Purpose of the Meeting

At the Meeting, the Company will ask stockholders to consider and vote upon the following proposals:

Purpose of the MeetingAt the Meeting, the Company will ask stockholders to consider and vote upon the following proposals:
 1.To re-elect

1. Re-elect seven directors to the Director NomineesBoard to serve on the Company’s Board of Directors until the next annual shareholders meeting and until their successors are duly elected and qualified;

qualified at the 2022 annual meeting of stockholders or until their earlier resignation or removal; and

 

2. Ratify the appointment of CZD as the independent registered public accounting firm of the Company for the fiscal year ending June 30, 2021.

 2.To re-appoint Wei
Record Date and Voting PowerOur Board fixed the close of business on April 30, 2021, as the record date for the determination of the outstanding shares of common stock entitled to notice of, and to vote on, the matters presented at the Meeting. As of the Record Date, there were 4,009,288 shares of common stock outstanding. Each share of common stock entitles the holder thereof to one vote. Accordingly, a total of 4,009,288 votes may be cast at the Meeting.
Quorum and Required Vote

A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present at the meeting if a majority of the common stock outstanding and entitled to vote at the Meeting is represented in person or by proxy. Abstentions and broker non-votes (i.e., shares held by brokers on behalf of their customers, which may not be voted on certain matters because the brokers have not received specific voting instructions from their customers with respect to such matters) will be counted solely for the purpose of determining whether a quorum is present at the Meeting.

Proposal No. 1 (re-election of seven directors) requires the affirmative vote of a plurality of the shares of common stock represented in person or by proxy and entitled to vote in the re-election of directors at the Meeting. Abstentions and broker non-votes will have no effect on the re-election of directors; and

Proposal No. 2 (ratification of appointment of CZD to serve as our independent registered public accounting firm for thefiscal year ending June 30, 2018;2021) requires the affirmative vote of the majority of the shares present in person or represented by proxy at the Meeting and entitled to vote thereon. Abstentions and broker non-votes will have no direct effect on the outcome of this proposal.

Revocability of ProxiesAny proxy may be revoked by the person giving it at any time before it is voted. A proxy may be revoked by (A) sending to our Secretary, at Shineco, Inc., Room 1001, Building T5, DaZu Square, Daxing District, Beijing 100176, People’s Republic of China, either (i) a written notice of revocation bearing a date later than the date of such proxy or (ii) a subsequent proxy relating to the same shares, or (B) by attending the Meeting and voting in person.
Proxy Solicitation CostsThe cost of preparing, assembling, printing, and mailing this proxy statement and the accompanying form of proxy, and the cost of soliciting proxies relating to the Meeting, will be borne by the Company. If any additional solicitation of the holders of our outstanding shares of common stock is deemed necessary, we (through our directors and officers) anticipate making such solicitation directly. The solicitation of proxies by mail may be supplemented by telephone, telegram, and personal solicitation by officers, directors, and other employees of the Company, but no additional compensation will be paid to such individuals.
No Right of AppraisalNone of Delaware law, our Certificate of Incorporation, or our Bylaws provides for appraisal or other similar rights for dissenting stockholders in connection with any of the proposals to be voted upon at the Meeting. Accordingly, our stockholders will have no right to dissent and obtain payment for their shares.
Who Can Answer Your Questions about Voting Your SharesYou can contact Yuying Zhang at (+86) 10-58693193 or by sending a letter to the offices of the Company at Room 1001, Building T5, DaZu Square, Daxing District, Beijing 100176, People’s Republic of China, with any questions about proposals described in this proxy statement or how to execute your vote.
Principal OfficesThe principal executive offices of our Company are located at Room 1001, Building T5, DaZu Square, Daxing District, Beijing 100176, People’s Republic of China. The Company’s telephone number is (+86) -010-58693193.

 

4
 3.To transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.

 

Record Date and Voting PowerProposal No. 1 — Re-Election of Directors

 

Our Board fixed the closeconsists of business on May 2, 2018, as the record date for the determinationseven directors, all of the outstanding shares of Common Stock entitled to notice of, and to vote on, the matters presented at this Meeting. As of the Record Date, there were 21,234,072 shares of Common Stock outstanding. Each share of Common Stock entitles the holder thereof to one vote. Accordingly, a total of 21,234,072 votes may be cast at this Meeting.

Quorum and Required Vote

A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present at the meeting if a majority of the Common Stock outstanding and entitled to vote at the Meeting is represented in person or by proxy. Abstentions and broker non-votes(i.e.shares held by brokers on behalf of their customers, which may not be voted on certain matters because the brokers have not received specific voting instructions from their customers with respect to such matters) will be counted solely for the purpose of determining whether a quorum is present at the Meeting.

Proposal No. 1 (re-election of each of the Director Nominees) requires the affirmative vote of a plurality of the shares of Common Stock represented in person or by proxy and entitled to vote in the election of directors at the Meeting. Abstentions and broker non-votes will have no effect on the election of directors;

Proposal No. 2 (re-appointment of Wei to serve as our independent registered public accounting firm for year ending June 30, 2018) requires the affirmative vote of the majority of the shares present in person or represented by proxy at the Meeting and entitled to vote thereon. Abstentions and broker non-votes will have no direct effect on the outcome of this proposal; and

Revocability of Proxies

Any proxy may be revoked by the person giving it at any time before it is voted. A proxy may be revoked by (A) sending to our Secretary, at Shineco, Inc., Room 1001, Building T5, DaZu Square, Daxing District, Beijing, People’s Republic of China, either (i) a written notice of revocation bearing a date later than the date of such proxy or (ii) a subsequent proxy relating to the same shares, or (B) by attending this Meeting and voting in person.

Proxy Solicitation Costs

The cost of preparing, assembling, printing and mailing this proxy statement and the accompanying form of proxy, and the cost of soliciting proxies relating to this Meeting, will be borne by the Company. If any additional solicitation of the holders of our outstanding shares of Common Stock is deemed necessary, we (through our directors and officers) anticipate making such solicitation directly. The solicitation of proxies by mail may be supplemented by telephone, telegram and personal solicitation by officers, directors and other employees of the Company, but no additional compensation will be paid to such individuals.

No Right of Appraisal

None of Delaware law, our Certificate of Incorporation or our Bylaws provides for appraisal or other similar rights for dissenting stockholders in connection with any of the proposals to be voted upon at this Meeting. Accordingly, our stockholders will have no right to dissent and obtain payment for their shares.

4

Who Can Answer Your Questions About Voting Your Shares

You can contact Yuying Zhang at (+86) 10-87227366 or by sending a letter to the offices of the Company at Room 1001, Building T5, DaZu Square, Daxing District, Beijing, People’s Republic of China, with any questions about proposals described in this proxy statement or how to execute your vote.

Principal Offices

The principal executive offices of our Company are located at Room 1001, Building T5, DaZu Square, Daxing District, Beijing, People’s Republic of China. The Company’s telephone number at such address is (86) 512 6396-0022.

PROPOSAL NO. 1 — RE-ELECTION OF DIRECTORS

The nominees listed belowwhom have been nominated by the Nominating and Corporate Governance Committee of our Board (the “Nominating Committee”) and approved by our Board to stand for re-election as directors of the Company. Unless such authority is withheld, proxies will be voted for the re-election of the persons named below, each of whom has been designated as a nominee. If, for any reason, any nominee/director becomes unavailable for re-election, the proxies will be voted for such substitute nominee(s) as the Board may propose.

 

Board Qualifications and Director Nominees

We believe that the collective skills, experiences, and qualifications of our directors provide our Board with the expertise and experience necessary to advance the interests of our stockholders. While the Nominating and Corporate Governance Committee of our Board does not have any specific, minimum qualifications that must be met by each of our directors, the Nominating and Corporate Governance Committee uses a variety of criteria to evaluate the qualifications and skills necessary for each member of the Board. In addition to the individual attributes of each of our current directors described below, we believe that our directors should have the highest professional and personal ethics and values, consistent with our longstanding values and standards. They should have broad experience at the policy-making level in business, exhibit commitment to enhancing stockholder value, and have sufficient time to carry out their duties and to provide insight and practical wisdom based on their past experience.

 

The Director Nomineesdirector nominees recommended by the Board are as follows:

 

the board recommends the RE-election of these nominees:

Name Age Director
Since
 Independent Position
Yuying Zhang 70 2011 No Chairman and Director
Sai (Sam) Wang 36 2016 No Chief Financial Officer and Director*
Baolin Li 66 2019 No Director
Jin Liu 55 2020 Yes Director
Yanzeng An 42 2019 Yes Director
Ning Chen 51 2020 Yes Director
Harry Edelson 86 2019 Yes Director

* Mr. Sai (Sam) Wang has been our CFO since 2015 and director since 2016.

Nominee Information

NameYuying Zhang
Age: 70
 AgeCurrent Position
YuYing Zhang64ChairPrincipal Occupation: Chairman and Director of the Board, Chief Executive Officer, and DirectorCompany
   
Sai (Sam) WangDirector since: 32Business Experience:

2011Chief Financial Officer and Director of Tianjin Tenet Huatai Technological Development Co., Ltd. since 2003
   
 
Jiping Chen67DirectorChairman and CEO of Beijing Tenet-Jove Technological Development Co., Ltd. since December 2003
   
 
Ying (Teresa) Zhang38Director (Independent), Chairman of Audit Committeethe Board of Beijing Huiyin Ansheng Asset Management Co., Ltd. from April 2014 to December 2014
   
 
Yajun Shi39Director (Independent)General Manager of Tianjin Balas Technological Development Co., Chairman of Compensation CommitteeLtd. from 1995 to December 2003
   
 
Leiger Yongmin Yang40Director (Independent)Former Deputy director at the Army Institute of Integrative Medicine
   
Executive Director and Deputy General Manager at Shan Haidan Pharmaceutical Group from 1991 to 1994

Skills and Expertise:

knowledge and extensive experience in research and development and management

Sai (Sam) Wang
Age: 36
Principal Occupation: Chief Financial Officer of the Company
  
Hua YangDirector since: 46Business Experience:

2016Financial Controller of the Company from 2011 and 2015
 
Supervisory director of Shineco Zhisheng (Beijing) Bio-Technology Co., Ltd. since 2014
General Manager of Qingdao Yinghuanhai International Logistics Co., Ltd. since 2012
Manager of Corporate Finance of Citibank in Shenzhen from 2008 to 2011

Skills and Expertise:

 ●In-depth experience with our financial matters
 ●

Profound knowledge of our industry

Baolin Li
Age: 66
Principal Occupation:Director (Independent)of the Company
Director since:Business Experience:

 2019Legal Representative of Shanghai Jiazheng Investment Management Co., ChairmanLtd. since July 2013
Legal Representative of Nominating CommitteeYushe County Linbao Bio-energy Technology Co., Ltd. since February 2018
Legal Representative of Yushe County Guangyuan Forest Development Co., Ltd. since June 2018

Skills and Expertise:

 ●Great experience in biological industry

Jin Liu
Age: 55
Principal Occupation: Executive Vice-President of China Science & Merchants Investment Management Group
Director since:Business Experience:

2019● 

Independent Director of Jilin JLU Communication Design Institute Co., Ltd. (SHE: 300597) since 2017

Executive Vice-President of China Science & Merchants Investment Management Group since 2014

Skills and Expertise:

Expertise in risk control, information disclosure, and financial management of domestic and foreign listed companies

Yanzeng An
Age: 42
Principal Occupation: Partner and lawyer at Beijing Bright Law Firm
Director since:Business Experience:

2019

Partner and lawyer at Beijing Bright Law Firm since 2016

Criminal trial work at Beijing Shijingshan District Court from 2008 to 2015
Civil trial work at Dezhou Court in Shandong Province from 2002 to 2005

Skills and Expertise:

 ●Quality experience in the legal field

Ning Chen
Age: 51
Principal Occupation: President of Jicai Capital Management (Beijing) Co., Ltd
Director since:Business Experience:

2019● 

President of Jicai Capital Management (Beijing) Co., Ltd.

CEO of Jijing Caihua Capital Management Co., Ltd. from October 2017 to November 2018
Executive Vice President of China Science and Merchants Capital Management Group from June 2014 to October 2017
Vice President of Runjia Huasheng Investment Fund Management Co., Ltd. from September 2011 to June 2014

Skills and Expertise:

Great experience in financial management.

Harry Edelson
Age: 86
Principal Occupation: President of Edelson Technology, Inc.
Director since:Business Experience:

2019 ●

Founder of Edelson Technology Partners

President of Edelson Technology, Inc., a company involved in consulting, fundraising, M&A, and investments since 1980
Served on over 150 boards of directors (12 as chairman)
director of four private companies, Airwire, PogoTec, eChinaCash, and Pathway Genomics, and one public company, China Gerui

Skills and Expertise:

Decades of experience on Wall Street and various venture capital ventures

SPAC experience, vast board experience, and participated in numerous M&A transactions

 

Information Regarding the Company’s DirectorsCorporate Governance Practices and the NomineesPolicies

 

YuYing ZhangBoard and Committee Independence, age 64, has been Chairman

The Board determines whether each of Shineco since 2011 andour directors is the Chairman and CEO of the Company. He was the principal founder of Tenet-Jove, which was established in 1995 with his research and development of Luobuma functional fiber healthcare products. He has been the Chairman and CEO of Tenet-Jove since December 2003; under his leadership, Tenet-Jove has worked with more than 20 research institutions and enterprises and has obtained numerous national invention and new product patent rights for Luobuma product development. He also serves asconsidered independent. For a director to be considered independent, the director must meet the bright-line independence standards under the Nasdaq listing standards. The Board must also affirmatively determine that, in Tianjin Tenet Huatai Technological Development Co., Ltd. since 2003. From April 2014its opinion, each director has no relationship that would interfere with the directors’ exercise of independent judgment in carrying out the director’s responsibilities. In addition to December 2014, he was the ChairmanNasdaq listing standards, the Board will consider all relevant facts and circumstances in determining whether a director is independent. There are no family relationships among any of our directors and executive officers. The Board has determined that the following nominees satisfy the independence requirements of Nasdaq: Jin Liu, Yanzeng An, Ning Chen, and Harry Edelson.

Board Committees and Meetings

The Board held five meetings during fiscal year 2020. No director attended fewer than 75% the aggregate number of all meetings of the Board of Beijing Huiyin Ansheng Asset Management Co., Ltd. From 1995 to December 2003,and committees on which he or she served as general manager of Tianjin Balas Technological Development Co., Ltd. Prior to starting Tenet-Jove in 1995, he was the deputy director at the Army Institute of Integrative Medicine. From 1991 to 1994, he was the Executive Director and Deputy General Manager at Shan Haidan Pharmaceutical Group, where he was responsible for strategic development planning and marketing. Mr. Zhang is a senior economist with a bachelor’s degree from China Central Radio and Television University in China. Mr. Zhang was chosen as director because of his knowledge and extensive experience in research and development and management.

5

Sai (Sam) Wang, age 32, became our Chief Financial Officer in February 2015 and Director since 2016. Mr. Wang has worked for Shineco, Inc. since 2011 where he served as Financial Controller until his appointment as our Chief Financial Officer. Mr. Wang has been the supervisory director of Shineco Zhisheng (Beijing) Bio-Technology Co., Ltd. since 2014. He serves as the General Manager of Qingdao Yinghuanhai International Logistics Co., Ltd. since 2012. Prior to joining Shineco, he worked for Citibank in Shenzhen from 2008 until 2011, where he served as Manager of Corporate Finance. Mr. Wang obtained a Masters in Commerce with a concentration in applied finance from The University of Queensland in 2010. In 2008, he received a bachelor’s degree in Accounting from Griffith University in Australia. Mr. Wang was chosen as a director because he has profound knowledge of our industry and he is experienced with our financial matters.

Jiping Chen, age 67, has been a director for Shineco since 2011. Mr. Chen has served as Chairman, General Manager and Legal Representative of Ankang Longevity Group since 2006. Mr. Chen worked at Ankang Longevity Group where he was a marketing manager from 1985 to 1992.. He has also served as a supervisor of Ankang Longevity Pharmaceutical (Group) Traditional Chinese Medicine Management Co., Ltd. since 2015. Since 2014, he has been Executive Director of Ankang Longevity Pharmaceutical (Group) Ziyang Longevity Traditional Chinese Medicine Materials Planting Co., Ltd. Since 2011 he has served as a supervisor of Ankang Longevity Real Estate Development Co., Ltd. He has also served as the Chairman of Board and General Manager of Ankang Longevity Pharmaceutical Group Pharmaceutical Industry Co., Ltd. since 2008. During 2008 to 2014, he served as a director of Ankang Longevity Pharmaceutical Group Breeding and Planting Co., Ltd. Since 2004, he has been the legal representative and Chairman of Board of Ankang Longevity Pharmaceutical (Group) Traditional Chinese Medicine Decoction Pieces Co., Ltd. He serves as legal representative and General Manager of Ankang Longevity Pharmaceutical Group Chain Co., Ltd. since 2003. Since 2002, Mr. Chen has been the Chairman of Board and General Manager of Ankang Longevity Pharmaceutical Group Purchasing Station Co., Ltd. From February 1975 to September 1985, Mr. Chen worked at the Ankang Area Public Bus Company where he served as company staff. From February 1973 to January 1975, he worked for Ankang County. Mr. Chen completed his three-year college education in Chinese Traditional Medicine major in Shannxi College of Chinese Traditional Medicine in 1997. Mr. Chen was chosen as director because of his experience in the traditional Chinese medicine business and his familiarity with Ankang Longevity Group’s operations.

Ying (Teresa) Zhang, age 38, has been a director for Shineco since October 2014. From 2014 to July 2016, she had served as the director in Beijing Huiyin Ansheng Assets Management Co., Ltd., which is a related party to Shineco. Since October 2010, Ms. Zhang has served as a director for Mixbox Co. Ltd., an international chain store management company. From January 2010 through December 2010, she had served as the chief financial officer and a director of Cleantech Solutions International, Inc., a U.S. public company (NASDAQ: CLNT) that manufactures wind power equipment in China. Ms. Zhang has served as a director in Shiqiao (Tianjin) Investment Consulting Co., Ltd. since 2009. Ms. Zhang was previously an auditing manager at GC Alliance HK CPA in Beijing from July 2005 until January 2010, where she provided auditing services to China-based companies. From January 2003 through June 2005, Ms. Zhang served as a liaison officer for the Australian-Chinese Friendship Business Association, a trade organization, and from July 2000 to September 2002 she was an auditor at Ernst & Young in Beijing. Ms. Zhang is not currently working with or serving entities that are related to or affiliated with the Company. Ms. Zhang is a certified practicing accountant in Australia. She received a bachelor degree in international accounting from Renmin University in China in 1996 and a master’s degree in accounting from Macquarie University in Australia in 2005. Ms. Zhang was chosen to serve as a memberduring fiscal year 2020. All of the boardCompany’s directors attended last year’s annual meeting of directors because of her experience with U.S. GAAP, as well as her extensive prior work experience and educational background in the accounting field.

Yajun Shi, age 39, has been a director for Shineco since October 2014. He is an associate professor and supervisor of postgraduate education at Shaanxi University of Chinese Medicine, is currently the vice president of the College of Pharmacy of Shaanxi University of Chinese Medicine, and is the director of the instrument center and committee member of the Traditional Chinese Medicine Chinese Drugs Pharmaceutics Association. Mr. Shi graduated from Shaanxi University of Chinese Medicine in June 1999 with a doctor degree, and has been engaging in new medicine development in The Fourth Military Medical University, the Pharmaceutical Research Institute and Shaanxi Tiansen Medicine Development Company. In July 2003, Mr. Shi received his Master’s Degree from the College of Pharmacy of Shaanxi University of Chinese Medicine. In June 2012, Mr. Shi received Doctor of Medicine degree (M.D.) from Chengdu University of Traditional Chinese Medicine where he specialized in traditional Chinese medicine preparation. Mr. Shi’s major research efforts are focused on traditional Chinese medicine and health products, focusing on the basic study and application of a Chinese medicine nasal drug application system, the study of traditional Chinese medicine powder characterization, and the modification and the adaptability, as well as the research and development of, healthy foods. Mr. Shi has published more than 40 academic papers, and compiled and published six professional books. Mr. Shi was chosen as a director because of his extensive knowledge and research of traditional Chinese medicines.

6

Leiger Yongmin Yang, age 40, has been a director for Shineco since January 2015. He has served as a director in Beijing Lanzhong Time Internet Science and Technology Co., Ltd. since 2014. Mr. Yang founded in 2012 China Offshore Financial Group (COFG), a professional offshore financial services provider, focused on financial services for private equity and venture capital firms, outbound and inbound investments, international trading, family trusts, and tax planning. Prior to founding COFG, Mr. Yang served as the General Manager of the Offshore Incorporations Limited Group & Vistra Group (OV Group) beginning in 2010. The OV Group focuses on the formation and maintenance of offshore companies, fund formation and fund administration, immigration and trust services. Mr. Yang has also worked as Chief Editor of the Chinese Asian Venture Capital Journal since 2006, where he is responsible for content of the weekly Chinese Asian Venture Capital Journal. From 2003 to 2011, he was the director of Zhiyuan Rongtong Investment Management Consulting (Beijing) Co., Ltd. Mr. Yang has spent the major part of his career in the private equity and venture capital sectors. Mr. Yang holds a Bachelor of Journalism degree from Jilin University in China. He was chosen as a director because of his hands-on experience in the private equity and venture capital sectors and his strong network with leading venture capital and private equity firms, law firms, accounting firms and banks in China.

Hua Yang, age 46, has been a director for Shineco since 2016. Ms. Yang has been a Partner and attorney in the Grandall Law Firm in Beijing since March 2007. From 2006 to 2011, she served as a director of Beijing Shichen International Consulting Co., Ltd. Her practice area covers Corporation Law, foreign investments, international litigation and arbitration. She provides services in the industries including civil aviation, agriculture biotechnology and nuclear power. From 2001 to 2007, Ms. Yang was a lawyer in the Beijing Weiheng Law Firm. She was also a visiting attorney for Canada Fraser Milner Casgrain LLP and Pothier Delisle Law Office during 2002 to 2003. Before that, she was the Legal Manager of Weihai International Trust and Investment Corporation during 1995 to 1999. Ms. Yang received her degree of Master of Laws in Indiana University in 2006. She also graduated from Renmin University of China with a degree of Master of Laws in 2001. She obtained a Bachelor’s degree of Laws from Northwest University of Political Science and Law in 1995 in China. We have chosen Ms. Yang to serve as a director because of the perspective she brings to legal matters in China and her rich experience in Corporate Law and foreign investments.

Vote Required

Proposal No. 1 will be approved if a plurality of the total votes properly caststockholders either in person or by proxy atconference call. The Company expects the directors to attend the Meeting either in person or by the holders of Common Stock vote “FOR” the proposal. Abstentions and broker non-votes will have no effect on the result of the vote.conference call.

 

Recommendation of the

Board Committees

 

The Board unanimously recommends that you vote all of your shares “FOR” the re-election to the Board of all of the Director Nominees described in this Proposal No. 1.

Corporate Governance

Director Independence

Our Board reviewed the materiality of any relationship that each of our directors has with us, either directly or indirectly. Based on this review, it is determined that Ying (Teresa) Zhang, Yajun Shi, Leiger Yongmin Yang and Hua Yang are “independent directors” as defined by NASDAQ.

Committees of the Board of Directors

We have establishedcreated three standing committees: an audit committee,Audit Committee, a compensation committeeCompensation Committee, and a nominating and governance committee. EachNominating Committee. The Board has adopted a formal, written charter for each of the committees under which each committee operates. The charters can be found in the Corporate Governance section of the Board hasInvestor Relations tab on the compositionCompany’s website at http://tianyiluobuma.com. As a matter of routine corporate governance, each committee intends to review its charter and responsibilities described below.practices on an annual basis to determine whether its charter and practices are consistent with listing standards of Nasdaq.

 

Committee Composition

Director Audit Compensation Nominating
Jin Liu (1)(2)(3) (1) (1)
Yanzeng An (1)   (1)(2)
Harry Edelson (1) (1)  
Ning Chen   (1)(2) (1)

(1)Committee member;
(2)Committee chair;
(3)Our board has determined that we have at least one “audit committee financial expert,” as defined by the rules and regulations of the SEC and that is Jin Liu.

Audit Committee

 

Upon re-election, Ying (Teresa) Zhang, Hua Yang,Jin Liu, Yanzeng An, and Leiger Yongmin YangHarry Edelson will be members of our Audit Committee of the Board (the “Audit Committee”), where Ms. ZhangMr. Jin Liu shall serve as the chairman. All members of our Audit Committee satisfy the independence standards promulgated by the SEC and by NASDAQNasdaq as such standards apply specifically to members of audit committees.Audit Committees.

7

 

We have adopted and approved a charter for the Audit Committee. In accordance with our Audit Committee Charter, our Audit Committee shall perform several functions, including:

 

 evaluates the independence and performance of, and assesses the qualifications of, our independent auditor, and engages such independent auditor;
 approves the plan and fees for the annual audit, quarterly reviews, tax, and other audit-related services, and approves in advance any non-audit service to be provided by the independent auditor;
 monitors the independence of the independent auditor and the rotation of partners of the independent auditor on our engagement team as required by law;
 reviews the financial statements to be included in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and reviews with management and the independent auditors the results of the annual audit and reviews of our quarterly financial statements;
 oversees all aspects of our systems of internal accounting control and corporate governance functions on behalf of the Board;
 reviews and approves in advance any proposed related-party transactions and reports to the full Board on any approved transactions; and
 provides oversight assistance in connection with legal, ethical, and risk management compliance programs established by management and the Board, including Sarbanes-Oxley Act implementation, and makes recommendations to the Board regarding corporate governance issues and policy decisions.

It is determined that Ms. ZhangMr. Jin Liu possesses accounting or related financial management experience that qualifies herhim as an "audit“audit committee financial expert"expert” as defined by the rules and regulations of the SEC.

 

The Audit Committee held two meetings in fiscal year 2020.

Compensation Committee

 

Upon re-election, Ying (Teresa) Zhang, Leiger Yongmin Yang, Yajun ShiJin Liu, Harry Edelson, and Ning Chen will be members of our Compensation Committee of the Board (the “Compensation Committee”) and Mr. ShiNing Chen shall serve as the chairman. All members of our Compensation Committee are qualified as independent under the current definition promulgated by NASDAQ.Nasdaq. We have adopted a charter for the Compensation Committee. In accordance with the Compensation Committee’s Charter, the Compensation Committee is responsible for overseeing and making recommendations to the Board regarding the salaries and other compensation of our executive officers and general employees and providing assistance and recommendations with respect to our compensation policies and practices.

 

The Compensation Committee held four meetings in fiscal year 2020.

Nominating and Governance Committee

 

Upon re-election, Ying (Teresa) Zhang, Hua YangJin Liu, Yanzeng An, and Yajun ShiHarry Edelson will be the members of our Nominating and Governance Committee, where Mr. Hua YangMs. Yanzeng An shall serve as the chairwoman. All members of our Nominating and Governance Committee are qualified as independent under the current definition promulgated by NASDAQ.Nasdaq. Our Board adopted and approved a charter for the Nominating and Governance Committee. In accordance with the Nominating and Governance Committee’s Charter, the Nominating and Governance Committee is responsible to identify and propose new potential director nominees to the board of directors for consideration and review our corporate governance policies.

 

CompensationThe Nominating Committee Interlocks and Insider Participationheld four meetings in fiscal year 2020.

 

None ofBoard Role in Risk Oversight

Our Audit Committee is primarily responsible for overseeing our executive officers currently serves, and in the past year has not served, as a memberrisk management processes on behalf of the boardBoard, including with respect to cybersecurity risks. The Audit Committee receives reports from management on at least a quarterly basis regarding management’s assessment of directors or compensation committee of any entity that has one or more executive officers serving on our Board.risks to the Company.

 

In addition, the Audit Committee reports regularly to our Board, which also monitors our risk profile. The Audit Committee and the Board focus on the most significant risks we face and our general risk management strategies, while our management team coordinates responses to day-to-day risks.

Code of Conduct and Ethics

 

We have adopted a code of conduct and ethics (the “Code of Ethics”) applicable to our directors, officers, and employees in accordance with applicable federal securities laws and NASDAQNasdaq rules. The Code of Ethics is publicly available in the Corporate Governance section of the Investor Relations tab on the Company’s website at http://tianyiluobuma.com. We intend to post any amendments to or waivers from the Code of Ethics that apply to our principal executive officer, principal financial officer, and principal accounting officer, or persons performing similar functions, on our website.

 

Family Relationships

There are no family relationships between or among the Director Nomineesdirector nominees or other executive officers of the Company.

 

98
 

 

Legal Proceedings Involving Officers and Directors

 

To the knowledge of the Company after reasonable inquiry, no Director Nomineedirector nominee or executive officers during the past ten10 years, or any promoter who was a promoter at any time during the past five fiscal years, has (1) been subject to a petition under the Federal bankruptcy laws or any state insolvency law was filed by or against, or a receiver, fiscal agent, or similar officer was appointed by a court for the business or property of such person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing; (2) been convicted in a criminal proceeding or is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses); (3) been the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities: (i) acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings, and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity; (ii) engaging in any type of business practice; or (iii) engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of Federal or State securities laws or Federal commodities laws; (4) been the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described in paragraph (3)(i) of this section, or to be associated with persons engaged in any such activity; (5) been found by a court of competent jurisdiction in a civil action or by the SEC to have violated any Federal or State securities law, and the judgment in such civil action or finding by the SEC has not been subsequently reversed, suspended, or vacated; (6) been found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated; (7) been the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of: (i) any Federal or State securities or commodities law or regulation; or (ii) any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or (iii) any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or (8) been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Securities Exchange Act of 1934, as amended, (“Exchange Act ”)or the “Exchange Act” (15 U.S.C. 78c(a)(26)), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29)), or any equivalent exchange, association, entity, or organization that has disciplinary authority over its members or persons associated with a member.

 

There are no material pending legal proceedings to which any of the individuals listed above is party adverse to the Company or any of its subsidiaries or has a material interest adverse to the Company or any of its subsidiaries.

 

Stockholder Communications with the Board

 

We have not implemented a formal policy or procedure by which our stockholders can communicate directly with our Board. Nevertheless, every effort will be made to ensure that the views of stockholders are heard by the Board, and that appropriate responses are provided to stockholders in a timely manner. During the upcoming year, our Board will continue to monitor whether it would be appropriate to adopt such a process.

 

Director Compensation

 

During the fiscal year ended June 30, 2020, we paid our independent directors an annual cash retainer of $10,000, except Harry Edelson who received $36,000. In the future, we may also provide stock, option, or other equity-based incentives to our directors for their service. We also reimbursed our directors for any out-of-pocket expenses incurred by them in connection with their services provided in such capacity.

The following table representsreflects all compensation awarded to, earned by, or paid to our directors for the fiscal year ended June 30, 2017.2020. Directors who are also officers do not receive any additional compensation for their services as directors.

 

Name Fees earned in
cash
($)
  Stock
awards
($)
  Option
awards
($)
  All other
compensation
($)
  Total
($)(1)
 
YuYing Zhang $-   -   -   -   - 
Sai (Sam) Wang $10,000   -   -   -   10,000 
Jiping Chen $10,000   -   -   -   10,000 
Ying (Teresa) Zhang $25,000   -   -   -   25,000 
Yajun Shi $10,000   -   -   -   10,000 
Leiger Yongmin Yang $10,000   -   -   -   10,000 
Hua Yang $10,000   -   -   -   10,000 
Name 

Fees

earned in

cash (1)
($)

  

Stock

Awards
($)

  Option
Awards
($)
  Non-Equity Incentive Plan Compensation ($)  Non-Qualified Deferred Compensation Earnings ($)  All Other Compensation ($)  Total
($)
 
Yuying Zhang  120,000               21,130   141,130 
Sai (Sam) Wang  99,600                  99,600 
Baolin Li  10,000                  10,000 
Jin Liu  10,000                  10,000 
Yanzeng An  10,000                  10,000 
Ning Chen  10,000                  10,000 
Harry Edelson  36,000                  36,000 

 

(1)All cash compensation was paid in RMB. The amounts in the foregoing table have been converted into U.S. Dollar at the conversion rate at 1 RMBRMB1 to 0.1475 USD.US$0.1466.

 

9

Executive Officers

 

Our current executive officers are as follows:

 

Name Age Position
Yuying ZhangOu Yang 6538 Chair of the Board, Chief Executive Officer and Directorof the Company
Sai (Sam) Wang 3236 Chief Financial Officer and Director of the Company

YuYing ZhangOu Yang, has been Chairmanour Chief Executive Officer since May 2021. From January 2020 to May 2021, Ms. Yang served as a partner of Shineco since 2011Wuhan Sinopharm Optical Valley Capital Management Co., Ltd., a subsidiary of China National Pharmaceutical Group Corporation and isan equity investment institution focusing on the Chairmanmedical and CEOhealthcare field, and was responsible for the investment and post-investment management of the Company. He wasfunds managed by the principal founder of Tenet-Jove, which was established in 1995 with his research and development of Luobuma functional fiber healthcare products. He has been the Chairman and CEO of Tenet-Jove since December 2003; under his leadership, the company has worked with more than 20 research institutions and enterprises and has obtained numerous national invention and new product patent rights for Luobuma product development. He also serves as a director in Tianjin Tenet Huatai Technological Development Co., Ltd. since 2003.company. From AprilMay 2014 to December 2014, he was the Chairman of the Board of Beijing Huiyin Ansheng Asset Management2019, Ms. Yang worked at multiple fund management companies and investment companies under Northeast Securities Co., Ltd. From 1995 to December 2003, he served asLtd (SHE: 000686), in various roles, including general manager, deputy general manager, director, and member of Tianjin Balas Technological Development Co., Ltd. Prior to starting Tenet-Joveinvestment committee, and was in 1995, he wascharge of or participated in the deputy director atinvestment of buyout funds in the Army InstituteUnited States and Europe. Ms. Yang obtained her bachelor’s degree and master’s degree in Finance from Jilin University School of Integrative Medicine. From 1991 to 1994, he was the Executive DirectorEconomics in 2006 and Deputy General Manager at Shan Haidan Pharmaceutical Group, where he was responsible for strategic development planning and marketing. Mr. Zhang is a senior economist with a bachelor degree from China Central Radio and Television University in China. Mr. Zhang was chosen as director because his knowledge and extensive experience in research and development and management.2008, respectively.

 

Sai (Sam) Wang, became our Chief Financial Officer in February 2015 and Director since 2016. Mr. Wang has worked for Shineco, Inc. since 2011, where he served as Financial Controller until his appointment as our Chief Financial Officer. Mr. Wang has been the supervisory director of Shineco Zhisheng (Beijing) Bio-Technology Co., Ltd. since 2014. He serveshas served as the General Manager of Qingdao Yinghuanhai International Logistics Co., Ltd. since 2012. Prior to joining Shineco, he worked for Citibank in Shenzhen from 2008 until 2011, where he served as Manager of Corporate Finance. Mr. Wang obtained a Masters in Commerce with a concentration in applied finance from Thethe University of Queensland in 2010. In 2008, he received a bachelor’s degree in Accounting from Griffith University in Australia. Mr. Wang was chosen as a director because he has profound knowledge of our industry and he is experienced with our financial matters.

 

Executive Compensation

The following table sets forth the compensation paid by us during the fiscal years ended June 30, 2020 and 2019 for services performed on our behalf with respect to the persons who served as our named executive officers as of June 30, 2020 and for the fiscal year ended June 30, 2020. Our named executive officers were Mr. Yuying Zhang and Mr. Sai (Sam) Wang. Mr. Zhang served as our Chief Executive Officer and Mr. Wang serves as our Chief Financial Officer.

Summary Compensation Table

Name and Principal Position Year Ended June 30,  Salary(1)
($)
  Bonus
($)
  Stock
Awards
($)
  Option
Awards
($)
  All Other Compensation ($)  Total
($)
 
Yuying Zhang(2) 2020   120,000            21,130(3)  141,130 
Chief Executive Officer 2019   120,000            18,180(3)  138,180 
                            
Sai (Sam) Wang 2020   99,600               99,600 
Chief Financial Officer 2019   99,600               99,600 

 

Summary Compensation Table

 

Name and 
Principal Position
 Fiscal
Year
 

Salary
(1) ($)

  Bonus
($)
  Stock
Awards
($)
  Option
Awards
($)
  Other
Compensation
($)
  Total
($)
 
                     
YuYing Zhang 2017  120,000         -              -           -   18,180(2)  138,180 
(CEO) (1) 2016  38,709   -   -   -   14,567(2)  53,276 
Sai (Sam) Wang 2017  99,600   -   -   -   10,000(3)  109,600 
(CFO) 2016  16,600   -   -   -   10,000(3)  26,600 

(1)Salaries were paid in RMB.

(2)(2)Mr. Zhang ceased to be our Chief Executive Officer on August 4, 2020.
(3)Mr. Zhang receives monthly payments for rent for his personal home and parking.

 

(3)Sai (Sam) Wang receives annual compensation for serving as a member of the Company’s board of directors.11

 

Grants of Plan Based Awards in the Fiscal Year Ended June 30, 20172020

 

During the fiscal year ended June 30, 2017,2020, the Company has not adopted any incentive plan.

 

Outstanding Equity Awards at Fiscal Year-EndYear Ended June 30, 2020

 

None.There were no equity awards granted to our officers or directors in the year ended June 30, 2020.

 

Employment Contracts, Termination of Employment, and Change-in-Control Arrangements

Generally

 

Under Chinese law, we may only terminate employment agreements without cause and without penalty by providing notice of non-renewal one month prior to the date on which the employment agreement is scheduled to expire. If we fail to provide this notice or if we wish to terminate an employment agreement in the absence of cause, then we are obligated to pay the employee one month’s salary for each year we have employed the employee. We are, however, permitted to terminate an employee for cause without penalty to our company, where the employee has committed a crime or the employee’s actions or inactions have resulted in a material adverse effect to us. At this time, we

We currently have no employment agreementscontract, agreement, plan, or arrangement, whether written or unwritten, that provides for payments to our executive officers at, following, or in connection with any termination, including without limitation resignation, severance, retirement, or a constructive termination of oura named executive officers.officer, or a change in control of the Company or a change in the executive officer’s responsibilities, with respect to each executive officer.

 

10

Section 1616(a) Compliance

 

Section 16(a) of the Exchange Act, requires our directors, officers, and persons who own more than 10% of our Common Stockcommon stock to file with the SEC initial reports of ownership and reports of changes in ownership of Common Stockcommon stock and other of our equity securities. To our knowledge, based solely on review of the copies of such reports furnished to us, as of the date of this proxy, all Section 16(a) filings applicable to officers, directors, and greater than 10% stockholders were made.

 

Security Ownership of Certain Beneficial Owners and Management

 

The following table sets forth information regarding the beneficial ownership of our common stock as of the Record Date for our officers, directors, director nominees and 5% or greater beneficial owners of common stock. There is no other person or group of affiliated persons, known by us to beneficially own more than 5% of our common stock.

We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. The person is also deemed to be a beneficial owner of any security of which that person has a right to acquire beneficial ownership within 60 days. Unless otherwise indicated, the person identified in this table has sole voting and investment power with respect to all shares shown as beneficially owned by him, subject to applicable community property laws.

The following table sets forth information, as of May 11, 2018, regarding the beneficial ownership of our common stock by any person known to us to be the beneficial owner of more than 5% of the outstanding common stock, by directors and certain executive officers, and by all of our directors and executive officers as a group. Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she, or it possesses sole or shared voting or investment power over that security or has the right to acquire securities within 60 days, including options and warrants that are currently exercisable or exercisable within 60 days.

Unless otherwise noted,indicated, we believe that all persons named in the table have sole voting and investment power with respect to all shares beneficially owned by them. The calculation of percentage of beneficial ownership is based on 4,009,288 shares of our officers and directors utilizecommon stock that were outstanding as of the following address for correspondence purposes: Shineco, Inc., Room 1001, Building T5, DaZu Square, Daxing District, Beijing, People’s Republic of China.Record Date.

 

Name and Address Title of
Class
 Amount and Nature of 
Beneficial Ownership
  Percent (%) of 
Class
 
Yuying Zhang common  1,343,140(1)  6.33%
Sai (Sam) Wang common  749,645   3.5%
Jiping Chen common  2,194,115   10.33%
Ying (Teresa) Zhang common  20,000   * 
Leiger Leiger Yongmin Yang common  -   - 
Hua Yang common  -   - 
Yajun Shi common  -   - 
           
All Officers and Directors as a Group (7 total) common  4,306,900   20.28%
           
5% Shareholders Not Mentioned Above:          
Xiaoyan Chen common  1,088,067   5.12%
Qiwei Wang common  1,109,908   5.23%
Name and Address of Beneficial Owner(1) Number of Shares of Common Stock Beneficially Owned  Percentage of Outstanding Shares of Common Stock 
Directors and Executive Officers of the Company:        
Ou Yang      
Yuying Zhang  536,703(2)  13.39%
Sai (Sam) Wang  517,294(3)  12.90%
Baolin Li  99,565   2.48%
Jin Liu      
Yanzeng An      
Ning Chen      
Harry Edelson      
All directors and executive officers as a group (eight individuals)  1,164,512   29.05%
Five Percent or More Stockholder:        
Wei Chang  227,537   5.68%

 

* less than 0.1%

  

(1)(1)Unless otherwise indicated, the business address of each of the persons and entities is Room 1001, Building T5, DaZu Square, Daxing District, Beijing, People’s Republic of China 100176.
(2)Includes 200,000409,687 shares owned by Min Zhao, the wife of YuYing Zhang. By virtuecommon stock, of this relationship, each of Ms. Zhao and Mr.which Yuying Zhang may be deemed to share beneficial ownershipexercise voting rights as a stockholder of the Company at his sole discretion pursuant to certain voting rights proxy agreements.
(3)Includes 434,000 shares of our company held by eachcommon stock, of them. Mr. Zhang disclaims beneficial ownershipwhich Sai (Sam) Wang may exercise voting rights as a stockholder of these shares.the Company at his sole discretion pursuant to certain voting rights proxy agreements.

 

1211
 

 

Certain Relationships and Related Party Transactions

 

DUE FROM RELATED PARTIESReview, Approval, or Ratification of Related Party Transactions

Our Audit Committee is responsible for reviewing and approving all related party transactions that are required to be disclosed under the applicable rules of the SEC and Nasdaq, when appropriate, and authorizing or ratifying all such transactions in accordance with written policies and procedures established by our board of directors from time to time. The Audit Committee may approve or ratify related party transaction only if it determines in good faith that under all the circumstances, the transaction is fair to us.

A director may vote in respect of any contract or transaction in which he or she is interested, provided, however that the nature of the interest of any director in any such contract or transaction shall be disclosed by him or her at or prior to its consideration and any vote on that matter. A general notice or disclosure to the directors or otherwise contained in the minutes of a meeting or a written resolution of the directors or any committee thereof of the nature of a director’s interest shall be sufficient disclosure and after such general notice it shall not be necessary to give special notice relating to any particular transaction. A director may be counted for a quorum upon a motion in respect of any contract or arrangement which he or she shall make with our company, or in which he or she is so interested and may vote on such motion.

We have a policy under which we are prohibited from making or renewing any personal loan to our executive officers or directors in accordance with Section 13(k) of the Exchange Act. The related party transactions with Yuying Zhang, our director and former Chief Executive Officer, described in this section occurred prior to adoption of this policy, and as such, these transactions were not subject to such prohibition. As of date of the Annual Report on Form 10-K filed on September 28, 2020 with the SEC, all outstanding amounts due from any loans to executive officers or directors have been collected in full.

Transactions

Members of the current management team are the owners of the VIEs in the PRC.

Due from Related Parties

 

The Company had previously made temporary advances to certain shareholdersstockholders (listed below) of the Company and to other entities that are either owned by family members of those shareholdersstockholders or to other entities that the Company has investments in. Those advances are due on demand, non-interest bearing.

 

As of March 31, 2018 and June 30, 2017,2020 and 2019, the outstanding amounts US$ due from related parties consist of the followingfollowing:

 

  March 31,
2018
  June 30,
2017
 
       
Yang Bin $159,218  $147,550 
Zhang Xin  98,716   91,480 
Chang Song  62,891   73,037 
Zhang Xinyu  -   61,441 
Zhang Hua  -   28,034 
Beijing Huiyinansheng Asset Management Co., Ltd  23,883   22,132 
Zhang Yuying  -   15,567 
Wang Qiwei  64,485   8,117 
Tian Shuangpeng  -   1,475 
  $409,193  $448,833 
  

June 30, 2020

  

June 30, 2019

 
       
Bin Yang $42,434  $43,688 
Beijing Huiyinansheng Asset Management Co., Ltd(1)  21,217   21,873 
Beijing Shengguang Tianyi Clothing Co., LTD(2)     63,911 
Qiwei Wang  57,288   58,981 
Total due from related parties $120,939  $188,453 

 

DUE TO RELATED PARTIES

(1)This company is wholly owned by one of the Company’s senior management.
(2)This company is wholly owned by one of the Company’s stockholders.

13

Due to Related Parties

 

As of March 31, 2018 and June 30, 2017,2020 and 2019, the Company had related party payables of US$ 206,8851,355,919 and US$ 257,880,234,500, respectively, mainly due to the principal shareholdersstockholders or certain relatives of the shareholdersstockholders of the Company who lend funds for the Company’s operations. The payables are unsecured, non-interest bearing, and due on demand.

 

  March 31,
2018
  June 30,
2017
 
       
Wu Yang  101,979   94,505 
Wang Sai  6,878   71,942 
Zhao Min  98,028   91,433 
  $206,885  $257,880 
  

June 30, 2020

  

June 30, 2019

 
       
Yang Wu(1) $90,598  $93,275 
Sai (Sam) Wang(2)  90,629   8,738 
Jiping Chen  3,024   989 
Yuying Zhang  -   2,913 
Guocong Zhou(3)  648,308   - 
Baolin Li  353,619   - 
Min Zhao(4)  169,741   128,585 
Total due to related parties $1,355,919  $234,500 

 

SALES TO RELATED PARTIES

(1)Yang Wu is the wife of Weixing Yin, one of our former Directors.
(2)Sai (Sam) Wang is our Chief Financial Officer and Director. The Company paid Mr. Wang $90,629 for the related party payables in the fiscal year ended June 30, 2020.
(3)Guocong Zhou ceased to be our Chief Executive Officer on May 5, 2021.
(4)Min Zhao is the wife of Yuying Zhang, our Chair of the Board and former Chief Executive Officer.

Sales to Related Parties

 

For the ninefiscal years ended June 30, 2020 and three months ended March 31, 2018,2019, the Company recorded sales to Shaanxi Pharmaceutical Group Pai’ang Medicine Co. Ltd. (“Shaanxi Pharmaceutical Group”), a related party, (our VIE entity, Ankang Longevity Pharmaceutical (Group) Co., Ltd. (“Ankang Longevity Group”) is a 49% participant in two equity investment companies with Shaanxi Pharmaceutical Group), of US$ 2,388,4882,990,910 and US$ 786,854, respectively. For the nine and three months ended March 31, 2017, the Company recorded sales to Shaanxi Pharmaceutical Group  of US$ 2,562,560 and US$ 879,956,3,405,982, respectively. As of March 31, 2018 and June 30, 2017,2020 and 2019, the balance of accounts receivable due from Shaanxi Pharmaceutical Group Pai’ang Medicine Co. Ltd. was US$ 2,927,7051,567,160 and US$ 2,205,453,2,706,111, respectively.

 

Review, Approval orProposal No. 2 — Ratification of Transactions with Related PersonsAppointment of Independent Registered Public Accounting Firm

 

OurWhile stockholder ratification of the Company’s independent registered public accountants is not required by our Certificate of Incorporation, Bylaws, or otherwise, the Audit Committee consistingand management believe that it is desirable and a matter of good corporate practice for stockholders to ratify the Company’s selection of the independent directors, is charged with reviewing and approving all agreements and transactions with related parties.

12

PROPOSAL NO. 2 — RE-APPOINTMENT OF INDEPENDENT REGISTRED PUBLIC ACCOUNTING FIRM

registered public accountants. The Audit Committee has selected WeiCZD to serve as the independent registered public accounting firm of the Company for the fiscal year ending June 30, 2018.

We2021. Therefore, we are asking ourrequesting that stockholders approve the proposal to re-appoint Weiratify the appointment of CZD as our independent registered public accounting firm.

The Audit Committee values the input of our stockholders. In the event ourthat stockholders fail to ratify the appointment,do not approve this proposal, the Audit Committee may reconsider this appointment.

We have been advised by WeiCZD that neither the firm nor any of its associates had any relationship during the last fiscal year with our Company other than the usual relationship that exists between independent registered public accountant firms and their clients. Representatives of WeiCZD are not expected to attend the Meeting in person and therefore are not expected to be available to respond to any questions. As a result, representatives of WeiCZD will not make a statement at the Meeting.

 

Principal Accountant Fees and ServicesThe Board recommends that you vote “for” ratifying the appointment of CZD to serve as the Company’s independent registered public accounting firm for the FISCAL year endING June 30, 2021.

 

Audit Fees.Change of Independent Registered Public Accounting Firm

 

The aggregate fees billed byAs previously disclosed in the Current Report on Form 8-K filed with the SEC on January 22, 2019 (the “January 2019 Form 8-K”), on January 15, 2019, the Company decided to change its independent registered public accounting firm for the annual report of the fiscal year ended June 30, 2019 and the remainder of the fiscal year ended June 30, 2019. On January 15, 2019, the Board approved the appointment of CZD as the Company’s independent registered public accounting firm for the Company’s fiscal year ended June 30, 2019 and the dismissal of Wei, Wei & Co., LLP for professional services rendered for(“Wei Wei”) from that role, each effective as of January 15, 2019.

During the audit of our annual financial statements, review of the financial information included in our Forms 10-Q for the respective periods and other required filings with the SEC for thefiscal years ended June 30, 2018 and 2017, and 2016 totaled $150,000the subsequent interim period through January 22, 2019, there were (i) no “disagreements” (as that term is described in Item 304(a)(1)(iv) of Regulation S-K and $210,000, respectively. The above amounts include interimthe related instructions) between the Company and Wei Wei on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to Wei Wei’s satisfaction, would have caused Wei Wei to make reference thereto in their reports, and (ii) no “reportable events” (as that term is described in Item 304(a)(1)(v) of Regulation S-K) except that Wei Wei advised the Company of material weaknesses related to ineffective disclosure controls and procedures as the Company did not have a Chief Financial Officer that is familiar with the accounting and audit fees, as well as attendance at audit committee meetings.reporting requirements of a U.S. publicly-listed company, and it did not have U.S. GAAP full-time qualified personnel in the accounting department to monitor the recording of the daily transactions and the lack of segregation of duties for accounting personnel who prepared and reviewed the journal entries during the fiscal years ended June 30, 2018 and 2017.

 

All Other Fees.The Company provided Wei Wei with a copy of the disclosures made within the January 2019 Form 8-K and requested that Wei Wei furnish a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with such disclosures. A copy of Wei Wei’s letter, dated January 22, 2019, was filed as Exhibit 16.1 to the January 2019 Form 8-K.

 

NoneDuring the fiscal year ended June 30, 2018, and the subsequent interim period through January 15, 2019, neither the Company nor anyone on its behalf consulted with CZD regarding (i) the application of accounting principles to a specified transaction, (ii) the type of audit opinion that might be rendered on the Company’s financial statements by CZD, in either case where written or oral advice provided by CZD would be an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issues, or (iii) any other matter that was the subject of a disagreement between us and our former auditor, Wei Wei or was a reportable event (as described in Items 304(a)(1)(iv) or Item 304(a)(1)(v) of Regulation S-K, respectively).

 

Fees Paid to the Independent Registered Public Accounting Firm

Aggregate fees billed to the Company for services rendered by CZD for the fiscal years ended June 30, 2020 and 2019 were:

  2020  2019 
Audit Fees(1) $195,000  $195,000 
Audit-Related Fees(2)      
Tax Fees(3)      
All Other Fees(4)      
Total Fees $195,000  $195,000 

(1)Audit Fees –This category includes the audit of our annual financial statements, review of financial statements included in our Quarterly Reports on Form 10-Q, and services that are normally provided by independent auditors in connection with statutory and regulatory filings or the engagement for fiscal years. This category also includes advice on audit and accounting matters that arose during, or as a result of, the audit or the review of interim financial statements.
(2)Audit-Related Fees – This category consists of assurance and related services by our independent auditor that are reasonably related to the performance of the audit or review of our financial statements and are not reported above under “Audit Fees.” The services for the fees disclosed under this category include consultation regarding our correspondence with the SEC.
(3)Tax Fees – This category consists of professional services rendered by our independent auditors for tax compliance and tax advice. The services for the fees disclosed under this category include tax return preparation and technical tax advice.
(4)All Other Fees –This category consists of fees for other miscellaneous items such as travel and out-of-pocket expenses.

15

Policies and Procedures Relating to Approval of Services by our Independent Registered Public Accountants

 

The Audit Committee is solely responsible for the approval in advance of all audit and permitted non-audit services to be provided by our independent registered public accounting firms (including the fees and other terms thereof), subject to thede minimusexceptions for non-audit services provided by Section 10A(i)(1)(B) of the Exchange Act, which services are subsequently approved by the Audit Committee prior to the completion of the audit. None of the fees listed above are for services rendered pursuant to suchde minimus exceptions.

 

The Audit Committee of our Board of Directors has established its pre-approval policies and procedures, pursuant to which the Audit Committee approved the foregoing audit, tax, and non-audit services provided by WeiCZD in 2017.the fiscal years ended June 30, 2020 and 2019. Consistent with the Audit Committee’s responsibility for engaging our independent auditors, all audit and permitted non-audit services require pre-approval by the Audit Committee. The full Audit Committee approves proposed services and fee estimates for these services. One or more independent directors serving on the Audit Committee may be delegated by the full Audit Committee to pre-approve any audit and non-audit services. Any such delegation shall be presented to the full Audit Committee at its next scheduled meeting. Pursuant to these procedures, the Audit Committee approved the foregoing audit services provided by Wei.CZD.

 

Vote Required

Proposal No. 2 (the re-appointment by the Audit Committee of Wei to serve as our independent registered public accounting firm for the fiscal year ending June 30, 2018) will be approved if a majority of the total votes properly cast in person or by proxy at the Meeting by the holders of common stock vote “FOR” the proposal. Abstentions and broker non-votes will have no effect on the result of the vote.

Unless marked to the contrary, the shares represented by the enclosed proxy card will be voted “FOR” re-appointment of the appointment of Wei as the independent registered public accountants of the Company.

13

Recommendation of the Board

The Board unanimously recommends that you vote all of your shares “FOR” the re-appointment of Wei as independent registered public accountants as described in this Proposal No. 2.

Audit Committee Report

 

The primary purpose of the Audit Committee is to assist the Board in fulfilling its responsibility to oversee our financial reporting activities. The Audit Committee is responsible for reviewing with both our independent registered public accounting firm and management, our accounting and reporting principles, policies and practices, as well asand our accounting, financial, and operating controls and staff. The Audit Committee has reviewed and discussed our audited financial statements with management, and has discussed with our independent registered public accounting firm the matters required to be discussed by the Public Company Accounting Oversight Board’s (the“PCAOB” “PCAOB”) Rule 3200T. Additionally, the Audit Committee has received the written disclosures and the letter from our independent registered public accounting firm, as required by the applicable requirements of the PCAOB, and has discussed with the independent registered public accounting firm’s independence. Based upon such review and discussion, the Audit Committee recommended to the Board that the audited financial statements be included in our Annual Report on Form 10-K for the last fiscal year ended June 30, 20172020 for filing with the SEC. The Audit Committee has also approved, subject to stockholders’ ratification, the appointment of Centurion ZD CPA & Co. to serve as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2021.

 

Audit Committee
Jin Liu

Yanzeng An

Harry Edelson

The information contained in this proxy statement with respect to the Audit Committee’s report above and the independence of the members of the Audit Committee shall not be deemed to be “soliciting material” or to be “filed” with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933, as amended, (the“Securities Act” ), or the Exchange Act, except to the extent that the Company specifically incorporates it by reference in such filing.

 

16

OTHER MATTERS

Other Matters

 

Our Board knows of no other matter to be presented at the Meeting. If any additional matter should properly come before the Meeting, it is the intention of the persons named in the enclosed proxy to vote such proxy in accordance with their judgment on any such matters.

 

OTHER INFORMATIONOther Important Information

 

Deadline for Submission of Stockholder Proposals for 20192022 Annual Meeting of Stockholders

 

For any proposal to be considered for inclusion in our proxy statement and form of proxy for submission to the stockholders at our 20192022 Annual Meeting of Stockholders, it must be submitted in writing and comply with the requirements of Rule 14a-8 of the Exchange Act. Such proposals must be received by the Company at its offices at Room 1001, Building T5, DaZu Square, Daxing District, Beijing 100176, People’s Republic of China, Attention: Chief Executive Officer, no later than January 31, 2019.3, 2022.

 

If we are not notified of a stockholder proposal within a reasonable time prior to the time we send our proxy statement for our 2019 annual meeting, then2022 Annual Meeting of Stockholders, our Board will have discretionary authority to vote on the stockholder proposal, even though the stockholder proposal is not discussed in the proxy statement. In order to curtail any controversy as to the date on which a stockholder proposal was received by us, it is suggested that stockholder proposals be submitted by certified mail, return receipt requested, and be addressed to Shineco, Inc., Room 1001, Building T5, DaZu Square, Daxing District, Beijing 100176, People’s Republic of China, Attention: Chief Executive Officer. Notwithstanding, the foregoing shall not affect any rights of stockholders to request inclusion of proposals in our proxy statement pursuant to Rule 14a-8 under the Exchange Act nor grant any stockholder a right to have any nominee included in our proxy statement.

 

14

Proxy Solicitation

 

The solicitation of proxies is made on behalf of the Board and we will bear the cost of soliciting proxies. The transfer agent and registrar for our common stock, Island Stock Transfer, LLC,Transhare Corporation, as a part of its regular services and for no additional compensation other than reimbursement for out-of-pocket expenses, has been engaged to assist in the proxy solicitation. Proxies may be solicited through the mail and through telephonic or telegraphic communications to, or by meetings with, stockholders or their representatives by our directors, officers, and other employees who will receive no additional compensation therefor. We may also retain a proxy solicitation firm to assist us in obtaining proxies by mail, facsimile, or email from record and beneficial holders of shares for the Meeting. If we retain a proxy solicitation firm, we expect to pay such firm reasonable and customary compensation for its services, including out-of-pocket expenses.

 

We request persons such as brokers, nominees, and fiduciaries holding stock in their names for others, or holding stock for others who have the right to give voting instructions, to forward proxy material to their principals and to request authority for the execution of the proxy. We will reimburse such persons for their reasonable expenses.

 

Annual Report

 

The Annual Report is being sent with this Proxy Statementproxy statement to each stockholder and is available atwww.proxyandprinting.comhttp://tianyiluobuma.com as well as on the SEC’s website at www.sec.gov.www.sec.gov. The Annual Report contains our audited financial statements for the fiscal year ended June 30, 2017.2020. The Annual Report, however, is not to be regarded as part of the proxy soliciting material.

 

Delivery of Proxy Materials to Households

 

Only one copy of this proxy statement and one copy of our Annual Report are being delivered to multiple registered stockholders who share an address unless we have received contrary instructions from one or more of the stockholders. A separate form of proxy and a separate notice of the Meeting are being included for each account at the shared address. Registered stockholders who share an address and would like to receive a separate copy of our Annual Report and/or a separate copy of this proxy statement, or have questions regarding the householding process, may contact the Company’s transfer agent: Island Stock Transfer, LLC,Transhare Corporation, by calling (727) 289-0010,(303) 662-1112, or by forwarding a written request addressed to Island Stock Transfer, LLC, 15500 Roosevelt Blvd.Transhare Corporation, Bayside Center 1, 17755 North US Highway 19, Suite 301,# 140, Clearwater, FL 33760. 33764.

Promptly upon request, a separate copy of our Annual Report on Form 10-K and/or a separate copy of this proxy Statementstatement will be sent. By contacting Island Stock Transfer, LLC,Transhare Corporation, registered stockholders sharing an address can also (i) notify the Company that the registered stockholders wish to receive separate annual reports to stockholders, proxy statements, and/or Notices of Internet Availability of Proxy Materials, as applicable, in the future or (ii) request delivery of a single copy of annual reports to stockholders and proxy statements in the future if registered stockholders at the shared address are receiving multiple copies.

Many brokers, brokerage firms, broker/dealers, banks, and other holders of record have also instituted “householding” (delivery of one copy of materials to multiple stockholders who share an address). If your family has one or more “street name” accounts under which you beneficially own shares of our common stock, you may have received householding information from your broker, brokerage firm, broker/dealer, bank, or other nominee in the past. Please contact the holder of record directly if you have questions, require additional copies of this proxy statement or our Annual Report or wish to revoke your decision to household and thereby receive multiple copies. You should also contact the holder of record if you wish to institute householding.

 

Where You Can Find Additional Information

 

Accompanying this proxy statement is a copy of the Company’s Annual Report on Form 10-K for the year ended June 30, 2017.Report. Such Annual Report constitutes the Company’s Annual Reportannual report to its Stockholdersstockholders for purposes of Rule 14a-3 under the Exchange Act. Such Annual Report includes the Company’s audited financial statements for the 2017 fiscal year ended June 30, 2020 and certain other financial information, which is incorporated by reference herein. The Company is subject to the informational requirements of the Exchange Act and in accordance therewith files reports, proxy statements, and other information with the SEC. Such reports, proxy statements, and other information are available on the SEC’s website atwww.sec.gov. www.sec.gov. Stockholders who have questions in regard to any aspect of the matters discussed in this proxy statement should contact Yuying Zhang, our Chief Executive Officer,Chairman of the Board, at Room 1001, Building T5, DaZu Square, Daxing District, Beijing 100176, People’s Republic of China or by telephone on(+86) 10-8722736610-58693193.

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice & Proxy Statement and the Annual Report are available at http://tianyiluobuma.com.

  

15

 

SHINECO, INC.

FormAnnual Meeting of Proxy CardStockholders

June 15, 2021

9:00 p.m. EST

 

THIS PROXY IS SOLICITED ON BEHALF OF

THE BOARD OF DIRECTORS OF SHINECO, INC.

 

PROXY FOR 2018 ANNUAL MEETING OF SHAREHOLDERSThe undersigned stockholder of Shineco, Inc., a Delaware corporation (the “Company”), hereby acknowledges receipt of the Notice of Annual Meeting of Stockholders and the Proxy Statement, each dated May 10, 2021, and hereby appoints, if no person is specified, Yanzeng An as proxy, with full power of substitution, on behalf and in the name of the undersigned, to represent the undersigned at the annual meeting of stockholders to be held on June 15, 2021, at 9:00 p.m. EST, at Room 3106, Building B, Jianwai SOHO, Chaoyang District, Beijing, 100022, People’s Republic of China (the “Meeting”), or at any adjournment or postponement thereof, and to vote all shares of common stock which the undersigned would be entitled to vote if then and there personally present, on the matters set forth below (i) as specified by the undersigned below and (ii) in the discretion of any proxy upon such other business as may properly come before the Meeting, all as set forth in the Notice of the Annual Meeting of Stockholders and in the Proxy Statement furnished herewith.

 

Tuesday, June 19, 2018

THE BOARD RECOMMENDS A VOTE FOR

THE PROPOSAL AND NOMINEES.

I. To re-elect Yuying Zhang, Sai (Sam) Wang, Jiping Chen, Ying (Teresa) Zhang, Yajun Shi, Leiger Yongman Yang, and Hua Yang to serve on the Company’s Board of Directors until the next annual shareholders meeting and until their successors are duly re-elected and qualified; and

___ FOR___ AGAINST___ ABSTAIN

II. To re-appoint Wei, Wei & Co., LLP as the Company’s independent registered public accounting firm for year ending June 30, 2018.

___ FOR___ AGAINST___ ABSTAIN

This Proxy is solicited on behalf of the management of Shineco, Inc. This Proxy,proxy, when properly executed, will be voted in the manner directed herein by the undersigned shareholder.stockholder. If no direction is made, this Proxyproxy will be voted FOR“FOR” Proposals No. 1 and 2 and in the proposals described above.discretion of the proxy with respect to such other business as may properly come before the Meeting.

 

TO

Continued and to be signed on reverse side

VOTE ONLINE:www.proxyandprinting.com clickBY INTERNET

www.transhare.com (click on Vote Your Proxy and enter your control number)

 

TO VOTE BY EMAIL:akotlova@islandstocktransfer.comUse the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m., EST, June 13, 2021. Have your proxy card in hand when you access the website and follow the instructions to obtain your records and to create an electronic voting instruction form.

 

TO VOTE BY FAX:EMAIL

Please fax thisemail your signed proxy card to 1.727.289.0069Anna Kotlova at akotlova@bizsolaconsulting.com.

 

TO VOTE BY MAIL:Please sign, date and mail to

Anna Kotlova

15500 Roosevelt Blvd, Suite 301

Clearwater, FL 33760FAX

 

IMPORTANT:Please fax your signed proxy card to +1.727.269.5616.

VOTE BY MAIL

Mark, sign, and date this Proxyyour proxy card and return it in the postage-paid envelope we have provided or return it to Anna Kotlova, Transhare Corporation, 2849 Executive Dr, Suite 200, Clearwater FL 33762.

ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS

If you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards, and annual reports electronically via e-mail or the Internet. To sign exactly asup for electronic delivery, please provide your nameemail address below and check here to indicate your consent to receive or names appear hereon. If shares are held jointly, both owners must sign. Executors, administrators, trustees, guardians and others signingaccess proxy materials electronically in a representative capacity should give their full titles.future years. [  ]

Email Address:

THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.

The Board of Directors recommends voting FOR the following:

 

Signature of ShareholderVotes must be indicated (x) in Black or Blue ink.
 
PROPOSAL NO. 1:To re-elect seven director nominees listed in the accompanying proxy statement;FORWITHHOLD  
  
  
Signature of Joint Shareholder 
  
  
To vote for all nominees or withhold from voting for all nominees, mark here[  ] [  ]  
Dated:
To vote individually for each nominee:[  ][  ]
1.01 Yuying Zhang[  ][  ]
1.02 Sai (Sam) Wang[  ][  ]
1.03 Baolin Li[  ][  ]
1.04 Jin Liu[  ][  ]
1.05 Yanzeng An[  ][  ]
1.06 Ning Chen[  ][  ]
1.07 Harry Edelson[  ][  ]
FORAGAINSTABSTAIN
PROPOSAL NO. 2:Ratify the appointment of Centurion ZD CPA & Co. as the independent registered public accounting firm of the Company for the fiscal year ending June 30, 2021.[  ][  ][  ]

Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If an entity, please sign in the full entity name, by a duly authorized officer.
Stock Owner signs hereCo-Owner signs here
  

Date: